Replies to post #705977 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

meirluc,

Absolutely!; ). Dr. Linda Liau said “apparently all patients are living longer” and we see that in how the long lived patients come from many different categories of patients including low absolute lymphocyte count, older, unmethylated and recurrent GBM patients. Combos and adjuvants help unblock and stimulate the immune response even better for some classes of patients and this has been demonstrated even while the Phase 3 was ongoing so that improved outcomes can be had after initial approval from what is known. Best wishes.

[meirluc]

Edit post 705977, beginning of third paragraph should read:
This is shown by the fact that the mOS of the unmethylated GBM
Treatment patients (14.9 months) was not significantly different
than the mOS of the ECA's unmethylated GBM patients (14.6 months).